Scarica l'app Stockscreener
7.07
2.46%
0.17
Dopo l'orario di chiusura:
7.05
-0.02
-0.28%
Precedente Chiudi:
$6.90
Aprire:
$7.11
Volume 24 ore:
752.69K
Relative Volume:
1.35
Capitalizzazione di mercato:
$381.64M
Reddito:
$2.81M
Utile/perdita netta:
$-97.34M
Rapporto P/E:
-4.4747
EPS:
-1.58
Flusso di cassa netto:
$-91.47M
1 W Prestazione:
+15.52%
1M Prestazione:
+93.70%
6M Prestazione:
+83.64%
1 anno Prestazione:
-9.01%
Intervallo 1D:
$6.98
$7.475
Intervallo di 1 settimana:
$6.03
$7.475
Portata 52W:
$2.315
$10.13
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Nome
Fulcrum Therapeutics Inc
Settore
Industria
Telefono
617-651-8851
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Confronta FULC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
7.07 | 330.35M | 2.81M | -97.34M | -91.47M | -1.58 |
|
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-23 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Downgrade | Stifel | Buy → Hold |
| 2024-09-09 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-09-25 | Iniziato | Goldman | Neutral |
| 2023-08-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Aggiornamento | Stifel | Hold → Buy |
| 2023-05-04 | Downgrade | Goldman | Buy → Neutral |
| 2023-03-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Downgrade | Stifel | Buy → Hold |
| 2023-02-28 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Iniziato | Goldman | Buy |
| 2022-03-08 | Iniziato | Oppenheimer | Outperform |
| 2022-03-03 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-22 | Iniziato | Credit Suisse | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
| 2020-10-16 | Iniziato | Piper Sandler | Overweight |
| 2020-08-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-12 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2019-10-03 | Iniziato | H.C. Wainwright | Buy |
| 2019-08-12 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie
Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory - Insider Monkey
Fulcrum Therapeutics to Present at Upcoming Medical Meetings | FULC Stock News - GuruFocus
Fulcrum Therapeutics to Present at Upcoming Medical Meetings - Eagle-Tribune
FULC: Piper Sandler Raises Price Target for Fulcrum Therapeutics | FULC Stock News - GuruFocus
Fulcrum Therapeutics to Participate in the 46th Annual Goldman S - GuruFocus
Rare Disease Innovator Fulcrum Therapeutics Takes Stage at Elite Goldman Sachs Healthcare Conference - Stock Titan
Fulcrum Therapeutics (FULC) Target Price Raised Amid Key Data An - GuruFocus
Fulcrum gains as Leerink upgrades ahead of data for lead asset - MSN
Fulcrum Therapeutics (NASDAQ:FULC) Upgraded at Leerink Partners - Defense World
Leerink Partnrs Upgrades Fulcrum Therapeutics (NASDAQ:FULC) to Strong-Buy - Defense World
Leerink raises Fulcrum Therapeutics stock to Outperform By Investing.com - Investing.com Canada
Northern Trust Corp Buys 142,578 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics Shares Rise After Upgrade From Leerink - marketscreener.com
Fulcrum stock gains as Leerink upgrades (FULC:NASDAQ) - Seeking Alpha
Fulcrum Therapeutics (FULC) Receives Analyst Upgrade and Increas - GuruFocus
Leerink Partners Upgrades Fulcrum Therapeutics (FULC) - Nasdaq
Leerink Upgrades Fulcrum Therapeutics to Outperform From Market Perform, Adjusts Price Target to $12 From $4 - marketscreener.com
Fulcrum Therapeutics (FULC) Receives Analyst Upgrade on Positive Outlook | FULC Stock News - GuruFocus
Leerink Partners Upgrades Fulcrum Therapeutics, Inc. (FULC) to Outperform, Raises Price Target - Insider Monkey
Fulcrum Therapeutics at RBC Capital: Strategic Steps in Sickle Cell Treatment - Investing.com Canada
Cantor Fitzgerald Predicts FULC FY2025 Earnings - Defense World
Price T Rowe Associates Inc. MD Raises Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $6.67 Average Price Target from Analysts - Defense World
Cantor Fitzgerald Upgrades Fulcrum Therapeutics (FULC) - Nasdaq
Fulcrum Therapeutics Shares Rise After Cantor Fitzgerald Upgrade - marketscreener.com
Fulcrum Therapeutics (FULC) Upgraded to Overweight by Cantor Fit - GuruFocus
Cantor Fitzgerald Upgrades Fulcrum Therapeutics to Overweight From Neutral, Price Target is $10 - marketscreener.com
FULC Stock Upgraded to Overweight by Cantor Fitzgerald with $10 - GuruFocus
FULC Stock Upgraded to Overweight by Cantor Fitzgerald with $10 Target | FULC Stock News - GuruFocus
Fulcrum Therapeutics (FULC) Upgraded by Cantor Fitzgerald with P - GuruFocus
Fulcrum Therapeutics (FULC) Upgraded by Cantor Fitzgerald with Positive Outlook | FULC Stock News - GuruFocus
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Dimensional Fund Advisors LP - Defense World
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FULC Stock News - GuruFocus
Wells Fargo & Company MN Has $161,000 Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Monday - Defense World
Fulcrum therapeutics targets key data from PIONEER trial in Q3 2025 - MSN
Mariner LLC Buys Shares of 16,516 Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fulcrum Therapeutics, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsFULC - ACCESS Newswire
Fulcrum Therapeutics to Participate in Upcoming May Conferences - The Manila Times
Market Momentum Report: Fulcrum Therapeutics Inc (FULC)’s Negative Close at 5.35 - DWinneX
Lobbying Update: $40,000 of FULCRUM THERAPEUTICS lobbying was just disclosed - Nasdaq
Fulcrum Therapeutics (FULC) to Present PIONEER Data at Upcoming Conference Call | FULC Stock News - GuruFocus
Are Smart Investors Making the Right Decision? Fulcrum Therapeutics Inc (FULC) - Sete News
Fulcrum Therapeutics Inc (FULC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ... - Yahoo Finance
Fulcrum Therapeutics’ Positive Earnings Call Highlights - TipRanks
Earnings call transcript: Fulcrum Therapeutics Q1 2025 reveals improved net loss By Investing.com - Investing.com South Africa
Fulcrum Therapeutics Inc [FULC] stock for 1,831 USD was sold by Tourangeau Greg - knoxdaily.com
Fulcrum Therapeutics Inc Azioni (FULC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):